January 20th 2021, 2:00pm
The combination of Inlyta (axitinib) and the synthetic hormone octreotide acetate failed to significantly improve progression-free survival, compared to placebo with the synthetic hormone. However, the results indicated the Inlyta-based combination did improve disease response in patients versus the placebo-based combination.
August 26th 2020, 6:00pm
Often uncovered by accident, appendiceal cancers trigger few symptoms until they’re advanced and can be difficult to detect and treat.
April 14th 2020, 10:21pm
COVID-19 has forced many people into a “new normal” that they aren’t familiar with and may not be equipped to handle. But cancer survivors are more prepared than most to handle the ramifications of the pandemic.
September 27th 2019, 12:00am
Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) led to a 44% response rate in patients with high-grade neuroendocrine tumors, according to phase 2 study findings.
August 23rd 2019, 6:00pm
From celebrity news to a new partnership aimed to help patients and their caregivers, here’s what is making headlines in the cancer space this week.
June 15th 2019, 4:00pm
This essay was written by Tracey M. Hopkins nominating registered nurse Rubirosa Ison, St. Joseph’s Hospital-North, Lutz, Florida, for CURE®’s 2019 Extraordinary Healer® Award.
October 12th 2017, 7:03am
Before I was diagnosed, I had my share of illnesses, but none that slowed me down like cancer could.
October 4th 2017, 5:58am
Since my diagnosis of incurable and metastatic neuroendocrine cancer in 2010, it's really all been about me.
7 Recent Cancer-Related Quality of Life Updates Patients May Have Missed
5 Recent COVID-19 News and Updates That Patients With Cancer May Have Missed
FDA Approves Cabometyx-Opdivo For Metastatic RCC Treatment
Novel Therapy Granted Priority Review By FDA for Treatment of Anal Cancer Subset
